Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Asset Writedowns and Impairment (2023 - 2025)

BioNexus Gene Lab's Asset Writedowns and Impairment history spans 3 years, with the latest figure at $175818.0 for Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment rose 7305.98% year-over-year to $175818.0; the TTM value through Sep 2025 reached $57368.0, up 1177.68%, while the annual FY2023 figure was $6194.0, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q3 2025 was $175818.0 at BioNexus Gene Lab, up from -$122843.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $175818.0 in Q3 2025 and bottomed at -$122843.0 in Q4 2024.
  • The 3-year median for Asset Writedowns and Impairment is $2019.0 (2023), against an average of $11493.0.
  • The largest annual shift saw Asset Writedowns and Impairment tumbled 6184.35% in 2024 before it skyrocketed 7305.98% in 2025.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $2019.0 in 2023, then crashed by 6184.35% to -$122843.0 in 2024, then skyrocketed by 243.12% to $175818.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Asset Writedowns and Impairment are $175818.0 (Q3 2025), -$122843.0 (Q4 2024), and $2374.0 (Q3 2024).